Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

‘One hour is just nothing’: Toronto man honoured for 500th blood donation

December 13, 2025

Border Terrier “Brighty” Wins AKC Royal Canin National All-Breed Puppy and Junior Stakes

December 13, 2025

Posha review: this robot chef cooks better than me

December 13, 2025

GeeFi (GEE) Reveals Upcoming Decentralized Exchange Aimed at Improving User-Focused Trading

December 13, 2025

Inside the Ring of Fire: A tale of two First Nations and a road that could change everything

December 13, 2025
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantronix
Press Release

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantronix

By News RoomMarch 19, 20243 Mins Read
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantronix
Share
Facebook Twitter LinkedIn Pinterest Email
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantronix

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lantronix, Inc. (“Lantronix” or the “Company”) (NASDAQ: LTRX) and reminds investors of the April 23, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Lantronix To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $50,000 investing in Lantronix stock or options between May 11, 2023 and February 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/LTRX.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Lantronix overstated demand and/or its visibility into demand for its IoT products; (2) Lantronix’s customers were reducing elevated levels of inventory of IoT products, thereby causing a general slowdown in the Company’s business; (3) certain of Lantronix’s embedded IOT revenues expected from a customer design win were delayed to the next fiscal year; (4) as a result of all the foregoing, Lantronix anticipated lower sales for its embedded IOT solutions for fiscal year 2024; (5) accordingly, Lantronix was unlikely to meet its own previously issued guidance for fiscal year 2024; and (6) as a result, the Company’s public statements were materially false and/or misleading at all relevant times.

On February 8, 2024, Lantronix reported its financial results for its second quarter of fiscal 2024 and revised its full-year guidance, stating that “[t]he change in our annual guidance is primarily due to lower expected sales for our embedded IOT solutions as a result of two factors: a general slowdown in our broad-based channel business as customers work through their inventories, and an embedded compute design win in video applications that was slated for revenue in the second half of fiscal 2024 that pushed into fiscal 2025.”

On this news, Lantronix’s stock price fell $1.89 per share, or 32.53%, to close at $3.92 per share on February 9, 2024.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Lantronix’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8cccb513-acce-46c7-a85f-f8dd598c2689

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Border Terrier “Brighty” Wins AKC Royal Canin National All-Breed Puppy and Junior Stakes

GeeFi (GEE) Reveals Upcoming Decentralized Exchange Aimed at Improving User-Focused Trading

BexBack Launches No-KYC Trading Campaign Featuring 100x Leverage and Double Deposit Bonus

Mutuum Finance (MUTM) Nears Phase 6 99% Allocation as Roadmap Phase 2 Advances Rapidly

Meridianbet Partners with BETER to Deploy Fast-Betting Content Across Global Markets

DeFi Crypto Mutuum Finance (MUTM) Hits New Roadmap Milestones as V1 Remains on Track with Over $19M Raised

Mutuum Finance (MUTM) Approaches $20M Funding as Q4 V1 Launch Prep Intensifies with Halborn Security

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Alameda Health System reminds community: Apply for Medi-Cal before December 31, 2025

Editors Picks

Border Terrier “Brighty” Wins AKC Royal Canin National All-Breed Puppy and Junior Stakes

December 13, 2025

Posha review: this robot chef cooks better than me

December 13, 2025

GeeFi (GEE) Reveals Upcoming Decentralized Exchange Aimed at Improving User-Focused Trading

December 13, 2025

Inside the Ring of Fire: A tale of two First Nations and a road that could change everything

December 13, 2025

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

The Nex Playground and Pixel Buds 2A top our list of the best deals this week

December 13, 2025

BexBack Launches No-KYC Trading Campaign Featuring 100x Leverage and Double Deposit Bonus

December 13, 2025

Holiday 2025 shipping deadlines: USPS, UPS, FedEx, and more

December 13, 2025
Facebook X (Twitter) Pinterest TikTok Instagram
© 2025 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version